…
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Virpax Pharmaceuticals Inc, traded as VRPX on the Pink Sheets, has limited recent public disclosures and a sparse operating history, so available sources provide little detail about its operations or product portfolio. Because public information is limited, long-term growth drivers would depend on successful clinical development, regulatory approvals or licensing and commercialization outcomes, which may appeal to investors seeking speculative small‑cap pharmaceutical exposure.
Material risks include limited transparency and liquidity, high execution and financing risk common to microcap biopharma issuers, potential dilution, and regulatory or clinical failure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -21.65M | -12.06M | -4.34M | -3.31M | -2.64M |
| Net income | -21.46M | -12.15M | -4.49M | -3.43M | -2.64M |
| Selling general administrative | 11.08M | 7.19M | 2.90M | 2.56M | 1.48M |
| Ebit | -21.85M | -12.03M | -4.20M | -3.18M | -2.63M |
| Ebitda | -21.65M | -11.96M | -4.19M | -3.18M | -2.63M |
| Depreciation and amortization | 0.19M | 0.06M | 0.00M | - | - |
| Operating income | -21.85M | -12.03M | -4.20M | -3.18M | -2.63M |
| Other operating expenses | 21.85M | 12.03M | 4.20M | 3.18M | 2.63M |
| Interest expense | -0.19M | 0.09M | 0.15M | 0.12M | 0.01M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | 0.00M | -0.09M | -0.15M | -0.12M | -0.01M |
| Income tax expense | -0.19M | 0.09M | 0.15M | 0.12M | - |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 21.85M | 12.03M | 4.20M | 3.18M | 2.63M |
| Total other income expense net | 0.19M | -0.03M | -0.14M | -0.12M | -0.01M |
| Net income from continuing ops | -21.65M | -12.06M | -4.34M | -3.31M | -2.64M |
| Net income applicable to common shares | - | -12.06M | -4.34M | -3.31M | -2.64M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 9.63M | 19.67M | 39.57M | 0.47M | 0.05M |
| Other current assets | 0.49M | 0.68M | 2.73M | 0.00M | 0.00M |
| Total liab | 7.69M | 3.09M | 2.09M | 4.68M | 2.78M |
| Total stockholder equity | 1.93M | 16.58M | 37.48M | -4.22M | -2.73M |
| Deferred long term liab | - | - | - | 0.39M | - |
| Other current liab | 7.69M | 3.09M | 2.09M | 3.12M | 1.51M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -59.54M | -44.35M | -22.70M | -10.65M | -6.31M |
| Other assets | - | - | - | 0.39M | - |
| Cash | 9.14M | 19.00M | 36.84M | 0.05M | 0.04M |
| Total current liabilities | 7.69M | 3.09M | 2.09M | 3.66M | 2.78M |
| Net debt | -9.14M | -19.00M | -36.84M | 1.51M | 1.22M |
| Short term debt | - | - | - | 0.54M | 1.26M |
| Short long term debt | - | - | - | 0.54M | 1.26M |
| Short long term debt total | - | - | - | 1.57M | 1.26M |
| Other stockholder equity | 61.48M | 60.93M | 60.19M | 6.43M | 3.58M |
| Total current assets | 9.63M | 19.67M | 39.57M | 0.07M | 0.05M |
| Net tangible assets | - | - | 37.48M | -4.22M | -2.73M |
| Net receivables | - | - | - | 0.00M | 0.00M |
| Long term debt | - | - | - | 1.02M | - |
| Inventory | - | - | - | - | 0.00M |
| Accounts payable | 0.00M | 0.00M | 0.00M | 3.12M | 0.00M |
| Accumulated other comprehensive income | 0.00M | - | - | - | - |
| Common stock total equity | - | - | - | 0.00M | 0.00M |
| Non currrent assets other | - | - | - | 0.39M | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.39M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Change to liabilities | - | -0.69M | 1.34M | 0.92M | 0.45M |
| Net borrowings | - | -1.50M | 0.07M | 0.50M | 0.55M |
| Total cash from financing activities | 0.00M | 51.33M | 1.40M | 1.12M | 1.67M |
| Change to operating activities | - | -2.71M | -0.01M | 0.01M | -0.01M |
| Net income | -21.65M | -12.06M | -4.34M | -3.31M | -2.64M |
| Change in cash | -17.85M | 36.79M | 0.01M | -0.01M | -0.12M |
| Begin period cash flow | 36.84M | 0.05M | 0.04M | 0.05M | 0.17M |
| End period cash flow | 19.00M | 36.84M | 0.05M | 0.04M | 0.05M |
| Total cash from operating activities | -17.85M | -14.54M | -1.38M | -1.13M | -1.80M |
| Issuance of capital stock | 0.00M | 58.02M | 1.38M | 0.62M | 1.12M |
| Other cashflows from financing activities | - | -5.09M | 0.02M | 0.50M | 0.55M |
| Change to netincome | - | 0.91M | 1.63M | 1.24M | 0.40M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 3.06M | -3.40M | 1.33M | 0.93M | 0.44M |
| Stock based compensation | 0.75M | 0.97M | 1.47M | 0.68M | 0.38M |
| Other non cash items | - | -0.06M | 0.15M | 0.56M | 0.01M |
| Free cash flow | -17.85M | -14.54M | -1.38M | -1.13M | -1.80M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| VRPX Virpax Pharmaceuticals Inc |
- -% |
0.00 | - | - | - | 2.15 | 0.29 |
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony P. Mack M.B.A. | Chairman & CEO | 1962 |
| Mr. Christopher M. Chipman CPA, CPA | CFO & Corp. Sec. | 1972 |
| Dr. Jeffrey A. Gudin M.D. | Exec. VP, Chief Medical Officer & Director | 1965 |
| Mr. Gerald W. Bruce | Exec. VP of Commercial Operations & Director | 1957 |
| Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. | Chief Scientific Officer | NA |
| Shana Panzarella | Chief of Staff | NA |
| Mr. Gerald W. Bruce | CEO & Director | 1957 |
| Dr. Sheila A. Mathias J.D., M.B.A., Ph.D. | Chief Scientific Officer | 1968 |
| Dr. Jeffrey A. Gudin M.D. | Executive VP, Chief Medical Officer & Director | 1966 |
| Mr. Vinay Shah A.C.A., M.B.A. | CFO, Principal Financial Officer, Principal Accounting Officer & Corporate Secretary | 1963 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.